Abstract

Biological degradation of natural product glycosides involves, alongside hydrolysis, β-elimination for glycosidic bond cleavage. Here, we discover an O-glycoside β-eliminase (OGE) from Agrobacterium tumefaciens that converts the C3-oxidized O-β-d-glucoside of phloretin (a plant-derived flavonoid) into the aglycone and the 2-hydroxy-3-keto-glycal elimination product. While unrelated in sequence, OGE is structurally homologous to, and shows effectively the same Mn2+ active site as, the C-glycoside deglycosylating enzyme (CGE) from a human intestinal bacterium implicated in β-elimination of 3-keto C-β-d-glucosides. We show that CGE catalyzes β-elimination of 3-keto O- and C-β-d-glucosides while OGE is specific for the O-glycoside substrate. Substrate comparisons and mutagenesis for CGE uncover positioning of aglycone for protonic assistance by the enzyme as critically important for C-glycoside cleavage. Collectively, our study suggests convergent evolution of active site for β-elimination of 3-keto O-β-d-glucosides. C-Glycoside cleavage is a specialized feature of this active site which is elicited by substrate through finely tuned enzyme-aglycone interactions.

Biological degradation of glycosides involves, alongside hydrolysis, β-elimination for glycosidic bond cleavage. Here, the authors report an O-glycoside β-eliminase from Agrobacterium tumefaciens that converts the C3-oxidized O-β-d-glucoside of phloretin into the aglycone and the 2-hydroxy-3-keto-d-glycal elimination product, and suggest convergent evolution of β-eliminase active sites for the cleavage of natural product 3-keto-O-glycosides.

Details

Title
Enzymatic β-elimination in natural product O- and C-glycoside deglycosylation
Author
Bitter, Johannes 1 ; Pfeiffer, Martin 1 ; Borg, Annika J. E. 2   VIAFID ORCID Logo  ; Kuhlmann, Kirill 3 ; Pavkov-Keller, Tea 4   VIAFID ORCID Logo  ; Sánchez-Murcia, Pedro A. 5   VIAFID ORCID Logo  ; Nidetzky, Bernd 2   VIAFID ORCID Logo 

 Graz University of Technology, NAWI Graz, Institute of Biotechnology and Biochemical Engineering, Graz, Austria (GRID:grid.410413.3) (ISNI:0000 0001 2294 748X) 
 Graz University of Technology, NAWI Graz, Institute of Biotechnology and Biochemical Engineering, Graz, Austria (GRID:grid.410413.3) (ISNI:0000 0001 2294 748X); Austrian Centre of Industrial Biotechnology, Graz, Austria (GRID:grid.432147.7) (ISNI:0000 0004 0591 4434) 
 University of Graz, NAWI Graz, Institute of Molecular Biosciences, Graz, Austria (GRID:grid.5110.5) (ISNI:0000000121539003) 
 University of Graz, NAWI Graz, Institute of Molecular Biosciences, Graz, Austria (GRID:grid.5110.5) (ISNI:0000000121539003); BioTechMed-Graz, Graz, Austria (GRID:grid.452216.6); University of Graz, BioHealth Field of Excellence, Graz, Austria (GRID:grid.5110.5) (ISNI:0000 0001 2153 9003) 
 Medical University of Graz, Laboratory of Computer-Aided Molecular Design, Division of Medicinal Chemistry, Otto-Loewi Research Center, Graz, Austria (GRID:grid.11598.34) (ISNI:0000 0000 8988 2476) 
Pages
7123
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2886462784
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.